NVDA
NVIDIA Corporation
NVDA has the edge over RCAT overall, supported by stronger valuation and lower modeled downside.
RCAT
Red Cat Holdings, Inc.
RCAT's outlook is improving, though it still trails on the overall score.
NVDA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
NVDA's revenue, profitability, cash flow and balance sheet are all currently strong.
RCAT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
RCAT's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
NVDA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $166 | — |
| Current | 21x | $166 | — |
| Cheap | 44x | $345 | +108% |
| Fair | 65x | $511 | +207% |
| Expensive | 93x | $734 | +342% |
Historical ranges are pointers, not guarantees.
NVDA's PE is in its cheap range at 21x. If earnings grow as analysts expect, today's price would be 12x next year's earnings.
RCAT PE Valuation
RCAT has no meaningful PE right now: it lost money over the past year.
NVDA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Broad | |
| Moderate |
Analysts expect strong earnings and revenue growth for NVDA, but weaker profitability.
RCAT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect RCAT's revenue to grow and its profitability to improve, with its earnings holding steady.
NVDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.77 | +74% |
| Q3 2026 | $7.91 | +125% |
| Q2 2026 | $6.53 | +111% |
| Q1 2026 | $4.90 | +67% |
| Q4 2025 | $4.03 | +59% |
| Q3 2025 | $3.51 | +65% |
| Q2 2025 | $3.10 | +81% |
| Q1 2025 | $2.94 | +147% |
| Q4 2024 | $2.54 | +234% |
NVDA has the edge over RCAT on earnings quality, reporting a profit while its opponent remains loss making.
RCAT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.79 | +$0.04 |
| Q1 2026 | -$0.68 | +$0.16 |
| Q1 2023 | -$0.38 | -$0.07 |
| Q4 2022 | -$0.33 | +$0.27 |
| Q3 2022 | -$0.26 | +$0.33 |
| Q2 2022 | -$0.24 | +$0.32 |
RCAT lost $0.79 per share over the past year, about the same as its loss the year before.
NVDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $96.2B | +106% |
| Q2 2026 | $81.6B | +85% |
| Q1 2026 | $68.1B | +73% |
| Q4 2025 | $57B | +62% |
| Q3 2025 | $46.7B | +56% |
| Q2 2025 | $44.1B | +69% |
| Q1 2025 | $39.3B | +78% |
| Q4 2024 | $35.1B | +94% |
NVDA's revenue has grown year over year for 13 quarters in a row: $96.2B last quarter, up 106% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 66% | +5.4 points |
| Q2 2026 | 66% | +17 points |
| Q1 2026 | 65% | +3.9 points |
| Q4 2025 | 63% | +0.8 points |
| Q3 2025 | 61% | -1.2 points |
| Q2 2025 | 49% | -16 points |
| Q1 2025 | 61% | -0.5 points |
| Q4 2024 | 62% | +4.9 points |
NVDA has the edge over RCAT on profitability, with a higher operating margin.
RCAT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $20.2M | +527% |
| Q1 2026 | $15.5M | +849% |
| Q4 2025 | $26.2M | +1866% |
| Q3 2025 | $9.6M | +529% |
| Q2 2025 | $3.2M | +16% |
| Q1 2025 | $1.6M | -74% |
| Q4 2024 | $1.3M | -77% |
| Q4 2024 | $1.5M | -61% |
RCAT's revenue has grown year over year for five quarters in a row: $20M last quarter, up 527% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -191% | +202 points |
| Q1 2026 | -176% | +589 points |
| Q4 2025 | -91% | +616 points |
| Q3 2025 | -182% | +687 points |
| Q2 2025 | -393% | +54 points |
| Q1 2025 | -766% | -647 points |
| Q4 2024 | -707% | -631 points |
| Q4 2024 | -869% | -753 points |
RCAT's operating margin was −191% last quarter, up 202 points from the same quarter a year ago.
NVDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $21.4B | +59% |
| Q2 2026 | $48.6B | +86% |
| Q1 2026 | $34.9B | +124% |
| Q4 2025 | $22.1B | +32% |
| Q3 2025 | $13.5B | -0.3% |
| Q2 2025 | $26.2B | +75% |
| Q1 2025 | $15.6B | +38% |
| Q3 2024 | $13.5B | +113% |
NVDA has the edge over RCAT on cash generation, producing positive trailing cash flow while its opponent burns cash.
RCAT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$52.6M | -$39.4M |
| Q1 2026 | -$38.7M | -$22.5M |
| Q4 2025 | -$41.9M | -$25.7M |
| Q3 2025 | -$24.5M | -$14.4M |
| Q2 2025 | -$13.2M | -$10.8M |
| Q1 2025 | -$16.2M | -$13.8M |
| Q4 2024 | -$16.1M | -$12M |
| Q4 2024 | -$10.2M | -$5.7M |
RCAT has burned cash in almost every quarter: −$158M over the past year, against −$56M the year before.
NVDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -106M shares |
| 1 year | -1% | -247M shares |
| 3 years | -2.8% | -705M shares |
| 5 years | -4.1% | -1B shares |
| Available history | -1.8% | -435M shares |
NVDA has the edge over RCAT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $19.7B |
| Q2 2026 | $19.3B |
| Q1 2026 | $3.8B |
| Q4 2025 | $12.5B |
| Q3 2025 | $9.7B |
| Q2 2025 | $14.1B |
| Q1 2025 | $7.8B |
| Q4 2024 | $11B |
NVDA spent $55.3B buying back its own shares over the past year, up 30% from the year before.
RCAT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +13% | +16M shares |
| 1 year | +50% | +45.6M shares |
| 3 years | +146% | +81.2M shares |
| 5 years | +302% | +103M shares |
| Available history | +709% | +120M shares |
RCAT has 137M diluted shares, up 50% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
NVDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | -0.0x | Net Cash |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | -0.0x | Net Cash |
| Q3 2025 | -0.0x | Net Cash |
| Q2 2025 | -0.1x | Net Cash |
| Q1 2025 | -0.0x | Very low |
| Q4 2024 | -0.0x | Net Cash |
NVDA's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
RCAT Net Leverage
RCAT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.4 | Neutral |
| Stochastic | 18.1 | Oversold |
NVDA's weekly RSI is 33 (neutral) and its Stochastic is 18 (oversold).
RCAT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.5 | Neutral |
| Stochastic | 7.9 | Oversold |
RCAT's weekly RSI is 32 (neutral) and its Stochastic is 8 (oversold).
NVDA PE vs Technology Sector
| Metric | NVDA | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 28x | 25% below |
| PE % | 0 | 35 | 35 pts below |
NVDA is trading at 21x earnings, a 25% discount to the Technology sector's median of 28x.
RCAT PE vs Technology Sector
RCAT has no meaningful PE right now: it lost money over the past year.
NVDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $208.9 | 20% below |
| 20 week MA | $212.0 | 22% below |
| 50 week MA | $199.9 | 17% below |
| 100 week MA | $175.1 | 5.1% below |
| 200 week MA | $123.6 | 34% above |
NVDA has the edge over RCAT on trend strength, trading above more of its moving averages.
RCAT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.07 | 22% below |
| 20 week MA | $7.21 | 45% below |
| 50 week MA | $9.91 | 60% below |
| 100 week MA | $9.20 | 57% below |
| 200 week MA | $5.43 | 27% below |
RCAT is in a downtrend: it's below all five of its weekly moving averages, and 27% below its 200-week average.
NVDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.92 | $13.0 | +119% |
| 2021 | $13.0 | $29.6 | +128% |
| 2022 | $29.6 | $15.2 | -49% |
| 2023 | $15.2 | $49.5 | +226% |
| 2024 | $49.5 | $137.0 | +177% |
| 2025 | $137.0 | $190.5 | +39% |
| 2026 YTD | $190.5 | $166.2 | -13% |
NVDA has the edge over RCAT on returns for 2026, with the stronger performance.
RCAT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.28 | $1.75 | +37% |
| 2021 | $1.75 | $2.18 | +25% |
| 2022 | $2.18 | $0.77 | -65% |
| 2023 | $0.77 | $0.88 | +14% |
| 2024 | $0.88 | $12.3 | +1293% |
| 2025 | $12.3 | $8.30 | -32% |
| 2026 YTD | $8.30 | $3.94 | -53% |
RCAT's yearly returns have swung widely, from +1293% in 2024 to −65% in 2022. It's down 53% so far in 2026.